CN106699672B - A kind of olaparib amorphous article and preparation method thereof - Google Patents
A kind of olaparib amorphous article and preparation method thereof Download PDFInfo
- Publication number
- CN106699672B CN106699672B CN201510785406.XA CN201510785406A CN106699672B CN 106699672 B CN106699672 B CN 106699672B CN 201510785406 A CN201510785406 A CN 201510785406A CN 106699672 B CN106699672 B CN 106699672B
- Authority
- CN
- China
- Prior art keywords
- olaparib
- amorphous article
- preparation
- room temperature
- raw material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960000572 olaparib Drugs 0.000 title claims abstract description 55
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 title claims abstract 16
- 238000002360 preparation method Methods 0.000 title abstract description 19
- 239000000843 powder Substances 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 15
- 239000011261 inert gas Substances 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims abstract description 4
- 238000012546 transfer Methods 0.000 claims abstract description 4
- 238000003756 stirring Methods 0.000 claims abstract 2
- 239000007787 solid Substances 0.000 claims description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 239000007789 gas Substances 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 229910052786 argon Inorganic materials 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000001307 helium Substances 0.000 claims description 3
- 229910052734 helium Inorganic materials 0.000 claims description 3
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 claims description 3
- 238000001228 spectrum Methods 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 239000002904 solvent Substances 0.000 abstract description 3
- 238000003860 storage Methods 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 2
- FDLYAMZZIXQODN-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FDLYAMZZIXQODN-UHFFFAOYSA-N 0.000 description 40
- 238000004458 analytical method Methods 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 5
- 238000000634 powder X-ray diffraction Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 2
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 210000002659 acromion Anatomy 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- RLLPVAHGXHCWKJ-UHFFFAOYSA-N permethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 RLLPVAHGXHCWKJ-UHFFFAOYSA-N 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 108700020462 BRCA2 Proteins 0.000 description 1
- 102000052609 BRCA2 Human genes 0.000 description 1
- 101150008921 Brca2 gene Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 239000012661 PARP inhibitor Substances 0.000 description 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 1
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 description 1
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000010309 melting process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical class C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of olaparib amorphous articles and preparation method thereof; the olaparib amorphous article is composed with x-ray diffractogram of powder shown in FIG. 1; it can be by under inert gas protection; it directly heats olaparib raw material and is melted completely to it, then transfer of melt to temperature is room temperature or is cooled to below in the clean canister of room temperature or pours into the mixture of ice and water of stirring or be directly cooled to room temperature in 2~3 hours and be prepared in advance.Olaparib amorphous article of the present invention has good dissolubility and stability, and solvent residual amount is extremely low, all has significance to the preparation, storage and use of subsequent preparation；Also, preparation method of the present invention also have many advantages, such as simple process, yield are high, quality is stable, it is with short production cycle, be easily achieved scale.
Description
Technical field
The present invention is to be related to a kind of olaparib amorphous article and preparation method thereof, belongs to field of pharmaceutical chemistry technology.
Background technique
Olaparib (Olaparib), chemical name are as follows: 1- (cyclopropane carbonyl) -4- [5- [(3,4- dihydro -4- oxo -1-
Phthalazinyl) methyl] -2- fluorobenzoyl] piperazine, shown in chemical structure such as formula (I):
The medicine is formulated by biotechnological pharmaceutics company, Britain (KuDOS Pharmaceuticals), by U.S. A Sili
Continue to develop after health (AstraZeneca) corporate buyout, successively obtains European Union's medicine office (EMA) and U.S.'s food and medicine pipe
Reason office (FDA) preferential examination qualification goes through respectively on December 18th, 2014 and on December 19th, 2014 in Europe and the U.S.
Listing.Trade name LynparzaTM, for treating women's advanced ovarian cancer relevant to oophoroma BRCA gene defect.Aura pa
Buddhist nun is completely new oral Poly ADP ribose polymerase [poly (ADP-ribose) polymerase, PAR P] inhibitor,
BRCA1 or BRCA2 mutation is acted on, the defect of approach is repaired using DNA, preferentially kills cancer cell.Olaparib is as one
Kind PARP inhibitor, achieves preferable tumour in a clinical trial phase and random experiment compared with liposomal doxorubicin
Inhibiting effect.
KuDOS Pharmaceuticals company first reported the PARP inhibitory activity of this phthalazine derivative
(WO2004080976, US20050059663), and disclose the crystal form A (WO2008047082A) and crystal form L of olaparib
(WO2009050469A) and their preparation method.Now studies have shown that: olaparib is the low bioavailability of low-solubility
Drug, existing crystal form haves the defects that solubility is poor, is unfavorable for absorption of human body, and can change in production process
Object transformation of crystal is closed, it cannot be guaranteed that the stability of drug-eluting.Therefore, it is badly in need of finding at present a kind of both same with good solubility
When there is the olaparib kenel of good stability again, be suitable for the preparation of industrialization of preparation and meet the various performances of preparation wanting
It asks.
Summary of the invention
In view of the above-mentioned problems existing in the prior art and demand, both there is excellent dissolution the object of the present invention is to provide a kind of
Property simultaneously again with good stability olaparib amorphous article and preparation method thereof.
Olaparib amorphous article of the present invention has x-ray diffractogram of powder shown in FIG. 1 spectrum.
Furtherly, olaparib amorphous article of the present invention, under powder x-ray diffraction, 2 θ be 12.0~
There is a broad peak between 40.0 degree, is to have an acromion between 5.0~15.0 degree in 2 θ.
A method of olaparib amorphous article of the present invention is prepared, is included the following steps:
Under inert gas protection, it directly heats olaparib raw material and is melted completely to it；Then extremely by transfer of melt
Temperature is room temperature or is cooled to below in the clean canister of room temperature in advance, so that material is quickly cooled to solid；It is solid to gained again
Body is crushed, and gained powder is the olaparib amorphous article.
The method that another kind prepares olaparib amorphous article of the present invention, includes the following steps:
Under inert gas protection, it directly heats olaparib raw material and is melted completely to it；Then fusant is poured into and is stirred
In the mixture of ice and water mixed, so that material is quickly cooled to type；Filtering is collected solid powder, then is dried in vacuo to get institute
The olaparib amorphous article stated.
Another prepares the method for olaparib amorphous article of the present invention, includes the following steps:
Under inert gas protection, it directly heats olaparib raw material and is melted completely to it；Then stop heating, make to melt
Solid be cooled to room temperature in 2~3 hours, formed vitreous solid；Gained vitreous solid is crushed again, gained powder
End is the olaparib amorphous article.
Above-mentioned inert gas is nitrogen, helium or argon gas.
Above-mentioned olaparib raw material is any known kenel.
Compared with prior art, the present invention have following conspicuousness the utility model has the advantages that
Result of study of the invention is shown: olaparib amorphous article of the present invention, have good dissolubility and
Stability is of great significance to the preparation and storage of subsequent preparation；Especially, olaparib amorphous article of the present invention
Preparation method not only have many advantages, such as simple process, yield are high, quality is stable, it is with short production cycle, be easily achieved scale, and
And by the method, volatilization can be made to remove by being heated to melting process the solvent sandwiched in olaparib raw material used
Go, so that the solvent residual amount of the olaparib amorphous article made is significantly reduced, make subsequent preparation using safe
Property is improved significantly；Therefore, the present invention compared with the existing technology, is more suitable as the raw material of pharmaceutical preparation, has significant
Industrial application value.
Detailed description of the invention
Fig. 1 is the XRD spectra of olaparib amorphous article of the present invention；
Fig. 2 is the DSC spectrogram of olaparib amorphous article of the present invention.
Specific embodiment
Combined with specific embodiments below and attached drawing, the present invention is further explained.It should be understood that these embodiments are merely to illustrate
The present invention rather than limit the scope of the invention.In the following examples, the experimental methods for specific conditions are not specified, usually according to
Normal condition or according to the normal condition proposed by manufacturer.
XRD diagram described in embodiment is to measure to obtain using Bruker D8advance X-ray powder diffraction instrument, specifically
Test parameter is as follows:
Cu-Kα
Voltage: 40Kv
Electric current: 40mA
Divergent slit: automatic
Scan pattern: continuous
Scanning range: from 3.0-40.0 degree
Sampling step length: 0.0200 degree
Sweep speed: 0.1 second/step.
DSC figure described in embodiment is obtained using DSC8500 analysis-e/or determining, and specific test parameter is as follows:
Initial temperature: 45 DEG C
Gas flow rate: nitrogen, 20.0mL/min
The rate of heat addition: from 45 DEG C~300 DEG C, 10 DEG C/min.
Embodiment 1: the preparation of olaparib amorphous article
Embodiment 1.1
Under inert gas protection, it directly heats olaparib raw material and is melted completely to it；Then extremely by transfer of melt
Temperature is room temperature or is cooled to below in the clean canister of room temperature in advance, so that material is quickly cooled to solid；It is solid to gained again
Body is crushed.
Gained powder is taken to carry out X-ray powder diffraction analysis and dsc analysis.
Fig. 1 is the XRD spectra of gained powder, as seen from Figure 1: gained powder is olaparib amorphous article, is in 2 θ
There is a broad peak between 12.0~40.0 degree, is to have an acromion between 5.0~15.0 degree in 2 θ.
Fig. 2 is the DSC spectrogram of gained powder, as seen from Figure 2: gained powder turns crystalline substance in 210.6 DEG C or so heat releases.
Embodiment 1.2
Under inert gas protection, it directly heats olaparib raw material and is melted completely to it；Then fusant is poured into and is stirred
In the mixture of ice and water mixed, so that material is quickly cooled to type；Filtering is collected solid powder, is dried in vacuo at 55 DEG C.
Through X-ray powder diffraction analysis and dsc analysis, gained powder is the olaparib amorphous article.
Embodiment 1.3
Under inert gas protection, it directly heats olaparib raw material and is melted completely to it；Then stop heating, make to melt
Solid be cooled to room temperature in 2~3 hours, formed vitreous solid；Gained vitreous solid is crushed again.
Through X-ray powder diffraction analysis and dsc analysis, gained powder is the olaparib amorphous article.
Above-mentioned inert gas can be nitrogen, helium or argon gas.
Above-mentioned olaparib raw material can be any known kenel.
Embodiment 2: stability experiment
Olaparib amorphous article sample made from above-described embodiment 1.1-1.3 is taken to be handled as follows:
1. being placed 3 months under 40 DEG C, 75% humidity；
2. being placed 3 months under 25 DEG C, 65% humidity；
By showing this to above-mentioned sample during processing 0 month, 1 month, 2 months, 3 months sampling analyses (XRD)
The invention olaparib amorphous article under accelerated test condition (40 DEG C, 75% humidity) and room temperature storage condition (25 DEG C,
65% humidity) under do not occur kenel variation, be able to maintain good stability.
Embodiment 3: solubility experiment
Olaparib amorphous article sample made from above-described embodiment 1.1-1.3 and known crystal form A sample are taken, referring in
The 1.1 solubility parts (readding 0121-0124 sections of specification in detail) of embodiment 1 in state patent CN200980150172.4 carry out
1 hour solubility experiment, specific test result are shown in Table 1.
1 solubility test data (mg/mL) of table
| Medium | 1.1 sample of embodiment | 1.2 sample of embodiment | 1.3 sample of embodiment | Crystal form A sample |
| Water | 0.258 | 0.251 | 0.257 | 0.123 |
| 0.1M HCL (pH=1.2) | 0.286 | 0.278 | 0.285 | 0.128 |
| Phosphate buffer (pH 6.8) | 0.249 | 0.235 | 0.251 | 0.111 |
| 0.1M NaOH (pH=12.5) | 1.05 | 0.97 | 1.07 | 0.650 |
Seen from table 1: olaparib amorphous article of the present invention is relative to known crystal form A, with excellent molten
Xie Xing, the dissolution for being very beneficial for preparation absorb, and are more suitable for the medicine activity component of preparation, have apparent industrial application
Value has conspicuousness progress and unexpected effect compared with the existing technology.
Claims (6)
1. a kind of olaparib amorphous article, it is characterised in that: have x-ray diffractogram of powder shown in FIG. 1 spectrum.
2. a kind of method for preparing olaparib amorphous article described in claim 1, which comprises the steps of:
Under inert gas protection, it directly heats olaparib raw material and is melted completely to it；Then by transfer of melt to temperature
It is cooled to below in the clean canister of room temperature for room temperature or in advance, so that material is quickly cooled to solid；Again to obtained solid into
Row crushes, and gained powder is the olaparib amorphous article.
3. a kind of method for preparing olaparib amorphous article described in claim 1, which comprises the steps of:
Under inert gas protection, it directly heats olaparib raw material and is melted completely to it；Then fusant is poured into stirring
In mixture of ice and water, so that material is quickly cooled to type；Filtering is collected solid powder, then is dried in vacuo to get described
Olaparib amorphous article.
4. a kind of method for preparing olaparib amorphous article described in claim 1, which comprises the steps of:
Under inert gas protection, it directly heats olaparib raw material and is melted completely to it；Then stop heating, make consolidating for melting
Body is cooled to room temperature in 2~3 hours, forms vitreous solid；Gained vitreous solid is crushed again, gained powder is
For the olaparib amorphous article.
5. method according to any one of claim 2 to 4, it is characterised in that: the inert gas is nitrogen, helium
Or argon gas.
6. method according to any one of claim 2 to 4, it is characterised in that: the olaparib raw material is any
Known kenel.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510785406.XA CN106699672B (en) | 2015-11-16 | 2015-11-16 | A kind of olaparib amorphous article and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510785406.XA CN106699672B (en) | 2015-11-16 | 2015-11-16 | A kind of olaparib amorphous article and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106699672A CN106699672A (en) | 2017-05-24 |
| CN106699672B true CN106699672B (en) | 2019-10-29 |
Family
ID=58930949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510785406.XA Active CN106699672B (en) | 2015-11-16 | 2015-11-16 | A kind of olaparib amorphous article and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106699672B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3031777A1 (en) | 2018-01-31 | 2019-07-31 | Apotex Inc. | Crystalline form of olaparib |
| CN116554108B (en) * | 2023-05-10 | 2025-08-26 | 江苏海洋大学 | Co-amorphous compound containing olaparib, preparation method thereof, and pharmaceutical composition |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101528714A (en) * | 2006-10-17 | 2009-09-09 | 库多斯药物有限公司 | Polymorphs of 4- [ 3- (4-cyclopropanecarbonyl-piperazine-1-carbonyl) -4-fluoro-benzyl ] -2H-phthalazin-1-one |
| CN101821242A (en) * | 2007-10-17 | 2010-09-01 | 库多斯药物有限公司 | 4- [3- (4-cyclopropanecarbonyl-piperazine-1-carbonyl) -4-fluoro-benzyl ] -2H-phthalazin-1-one |
| CN102107008A (en) * | 2003-12-01 | 2011-06-29 | 库多斯药物有限公司 | DNA damage repair inhibitors for treatment of cancer |
-
2015
- 2015-11-16 CN CN201510785406.XA patent/CN106699672B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102107008A (en) * | 2003-12-01 | 2011-06-29 | 库多斯药物有限公司 | DNA damage repair inhibitors for treatment of cancer |
| CN101528714A (en) * | 2006-10-17 | 2009-09-09 | 库多斯药物有限公司 | Polymorphs of 4- [ 3- (4-cyclopropanecarbonyl-piperazine-1-carbonyl) -4-fluoro-benzyl ] -2H-phthalazin-1-one |
| CN101821242A (en) * | 2007-10-17 | 2010-09-01 | 库多斯药物有限公司 | 4- [3- (4-cyclopropanecarbonyl-piperazine-1-carbonyl) -4-fluoro-benzyl ] -2H-phthalazin-1-one |
Non-Patent Citations (2)
| Title |
|---|
| 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1;Keith A. Menear,等;《J. Med. Chem.》;20080919;第51卷;6581-6591 * |
| Efficient Fluoride-Catalyzed Conversion of CO2 to CO at Room Efficient Fluoride-Catalyzed Conversion of CO2 to CO at Room;Camille Lescot，等;《J. Am. Chem. Soc.》;20140404;第136卷;6142-6147 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106699672A (en) | 2017-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101412700B (en) | Crystal form and preparation of febuxostat | |
| CN101891738B (en) | Dasatinib polymorph, its preparation method and pharmaceutical composition | |
| CN106008515A (en) | New crystal form of ibrutinib and preparation method of new crystal form | |
| CN104788438B (en) | The net B crystal forms of En Gelie and its preparation | |
| CN106699672B (en) | A kind of olaparib amorphous article and preparation method thereof | |
| RS59782B1 (en) | Hydroxyethyl sulfonate of cyclin-dependent protein kinase inhibitor, crystalline form thereof and preparation method therefor | |
| TWI745289B (en) | A crystalline form of cyclin-dependent protein kinase inhibitor and preparation methods thereof | |
| CN102311382B (en) | Novel crystalline state of roflumilast and preparation method thereof | |
| CN106008529A (en) | Ibrutinib solvate and preparation method thereof | |
| CN108017638A (en) | A kind of preparation method of Li Gelieting crystal forms | |
| CN103833755A (en) | Crystal form B of Apixaban and preparation method thereof | |
| CN106083963A (en) | A kind of preparation method of Suo Feibuwei crystal formation 6 | |
| CN106074395A (en) | A kind of preparation method of isotretinoin microgranule | |
| CN105777651A (en) | Crystal form of poly adenosinediphosphate-ribose polymerase (PARP) inhibitor, preparation method for crystal form and medicinal use of crystal form | |
| CN103709156A (en) | Dasatinib polymorph medicine and preparation method thereof | |
| CN111018841A (en) | Allisartan isoproxil amorphous form, preparation method thereof and pharmaceutical composition containing amorphous form | |
| CN106478598B (en) | A kind of Vande Thani hydrate crystal and preparation method thereof | |
| CN111606816A (en) | Dezocine crystal form and preparation method thereof | |
| CN104829483B (en) | A kind of preparation method of Propacetamol Hydrochloride A crystal formation | |
| CN119371408B (en) | Amorphous allisartan medoxomil and preparation method thereof | |
| CN103724397B (en) | The preparation method of a kind of dutasteride's crystal formation I | |
| CN107629048B (en) | Crystal form of malate of tyrosine kinase inhibitor and preparation method thereof | |
| CN103360450B (en) | Two crystal forms of ginsenoside C-K and preparation method thereof | |
| CN108586556B (en) | Crystal form of pentostatin, preparation method and application thereof | |
| CN105218434A (en) | Carbinoxamine maleate crystal formation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |